Skip to main
ENLV

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex Therapeutics Ltd is experiencing a notable increase in trading volume, with their active-at-the-market (ATM) program strategically positioned to enhance liquidity for their Allocetra immunotherapy, ensuring operational momentum is preserved. The clinical trial results for Allocetra have shown significant improvements in both pain reduction and functional outcomes in patients aged 60 and older, a demographic that constitutes a substantial portion of the osteoarthritis market, thereby bolstering the drug's commercial potential. Furthermore, the ongoing favorable safety profile and the planning of additional studies for Allocetra suggest a robust pipeline that could further expand its applicability and market reach, positively influencing the company's financial outlook.

Bears say

Enlivex Therapeutics faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include potential adverse results from clinical studies, difficulties in securing partnerships for advancing treatments, and delays in obtaining regulatory approval for its lead immunotherapy, Allocetra. Additionally, concerns regarding market penetration, price volatility of associated digital assets, and the potential for dilution further complicate the company's financial prospects.

ENLV has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 2 analysts, ENLV has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.